David Nierengarten

David Nierengarten

Analyst-Equity chez
Wedbush Securities, Inc.
Finance
Consumer Services
Health Technology

Profil

Dr. David Nierengarten is a Senior Analyst at Wedbush Securities, Inc. Dr. David Nierengarten, Ph.D., has been a senior analyst covering small-mid cap biotech stocks with a heavy focus on oncology, rare disease and gene therapy.
His prior experience in venture capital and operations at a private biotechnology company, helps him succeed in analyzing both science and business models.
In addition, Dr. David Nierengarten, Ph.D.
has results in predicting Dendreon's looming bankruptcy, and several M&A events involving NPS Pharmaceuticals and Anacor.
Dr. David Nierengarten, Ph.D.
received his B.S.
in Biochemistry from the University of Wisconsin-Madison, and Ph.D.
in Molecular and Cell Biology from the University of California at Berkeley.

Postes actifs de David Nierengarten

SociétésPosteDébut
Analyst-Equity -

Anciens postes connus de David Nierengarten

SociétésPosteFin
Corporate Officer/Principal 30/11/2010
Analyst-Equity 30/06/2007
Corporate Officer/Principal 30/05/2007
Corporate Officer/Principal 31/12/2004
Voir l'expérience en détail de David Nierengarten

Formation de David Nierengarten

Expériences
Fonctions occupées

Actives

Inactives

Sociétés cotées

Entreprise privées

Relations

100 +

Relations au 1er degré

7

Entreprises liées au 1er degré

Homme

Femme

Administrateurs

Exécutifs

Sociétés liées

Entreprise privées7

Finance

Health Technology

Finance

Consumer Services

Consumer Services

Finance

Finance

  1. Bourse
  2. Insiders
  3. David Nierengarten
-40% : Prolongation exceptionnelle ➤➤➤➤
j
:
:
PROFITEZ-EN MAINTENANT
🔇